• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于全基因组 DNA 甲基化特征预测贝伐珠单抗联合新辅助化疗治疗乳腺癌的病理完全缓解。

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.

机构信息

Department of Environmental and Occupational Health, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

Department of Biostatistics, Colleges of Medicine and of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

出版信息

PLoS One. 2020 Apr 16;15(4):e0230248. doi: 10.1371/journal.pone.0230248. eCollection 2020.

DOI:10.1371/journal.pone.0230248
PMID:32298288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7162481/
Abstract

ClinicalTrials.gov Identifier: NCT00203502.

摘要

ClinicalTrials.gov 标识符：NCT00203502。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/b99228b26cf1/pone.0230248.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/4329e5e50c06/pone.0230248.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/cdac8255c8af/pone.0230248.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/2831955115cc/pone.0230248.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/b99228b26cf1/pone.0230248.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/4329e5e50c06/pone.0230248.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/cdac8255c8af/pone.0230248.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/2831955115cc/pone.0230248.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da66/7162481/b99228b26cf1/pone.0230248.g004.jpg

相似文献

1
Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.基于全基因组 DNA 甲基化特征预测贝伐珠单抗联合新辅助化疗治疗乳腺癌的病理完全缓解。
PLoS One. 2020 Apr 16;15(4):e0230248. doi: 10.1371/journal.pone.0230248. eCollection 2020.
2
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.贝伐珠单抗联合新辅助化疗治疗 HER2 阴性炎性乳腺癌患者（BEVERLY-1）：一项多中心、单臂、2 期研究。
Lancet Oncol. 2016 May;17(5):600-11. doi: 10.1016/S1470-2045(16)00011-5. Epub 2016 Mar 28.
3
The Inhibitory Effect of (-)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing Methylation and DNMT Activity.(-)-表没食子儿茶素没食子酸酯通过降低甲基化和 DNMT 活性抑制乳腺癌进展。
Molecules. 2019 Aug 9;24(16):2899. doi: 10.3390/molecules24162899.
4
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.评估接受新辅助化疗加贝伐单抗治疗的HER2阴性乳腺癌患者的早期反应生物标志物与长期生存的关系：II期PROMIX试验结果
Int J Cancer. 2018 Feb 1;142(3):618-628. doi: 10.1002/ijc.31070. Epub 2017 Oct 13.
5
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.SWOG S0800（NCI CDR0000636131）：在新辅助白蛋白结合型紫杉醇联合剂量密集型阿霉素和环磷酰胺方案中加入贝伐单抗，可提高炎性或局部晚期乳腺癌的病理完全缓解（pCR）率。
Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.
6
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.血管密度和标准化在乳腺癌患者新辅助贝伐单抗和化疗反应中的作用。
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2.
7
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.利用 [(18)F]-FDG PET 预测曲妥珠单抗和多西他赛新辅助治疗 HER2 阳性乳腺癌患者的反应，以及在 [(18)F]-FDG PET 预测无应答者中添加贝伐珠单抗（AVATAXHER）：一项开放标签、随机 2 期试验。
Lancet Oncol. 2014 Dec;15(13):1493-1502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30.
8
Methylation profiling of CpG islands in human breast cancer cells.人乳腺癌细胞中CpG岛的甲基化谱分析
Hum Mol Genet. 1999 Mar;8(3):459-70. doi: 10.1093/hmg/8.3.459.
9
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.Ⅱ期研究：新辅助每周紫杉醇联合白蛋白结合型紫杉醇和卡铂，联合贝伐珠单抗和曲妥珠单抗，用于治疗局部晚期 HER2+ 乳腺癌女性患者。
Clin Breast Cancer. 2011 Oct;11(5):297-305. doi: 10.1016/j.clbc.2011.04.002. Epub 2011 May 5.
10
[Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].[BRCA1和APC基因异常甲基化与原发性乳腺癌蒽环类新辅助化疗疗效的相关性]
Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):282-6.

引用本文的文献

1
DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.新辅助化疗后 DNA 甲基化变化与乳腺癌生存相关。
Breast Cancer Res. 2022 Jun 24;24(1):43. doi: 10.1186/s13058-022-01537-9.
2
Genome-Wide DNA Methylation Signatures Predict the Early Asymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer.全基因组DNA甲基化特征可预测乳腺癌患者早期无症状性阿霉素诱导的心脏毒性
Cancers (Basel). 2021 Dec 15;13(24):6291. doi: 10.3390/cancers13246291.
3
Deciphering the Methylation Landscape in Breast Cancer: Diagnostic and Prognostic Biosignatures through Automated Machine Learning.

本文引用的文献

1
Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study.乳腺癌化疗对白细胞 DNA 甲基化图谱和认知功能的影响：一项前瞻性研究。
Clin Epigenetics. 2019 Mar 12;11(1):45. doi: 10.1186/s13148-019-0641-1.
2
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.分化状态可塑性是基底样乳腺癌的一种可靶向的耐药机制。
Nat Commun. 2018 Sep 19;9(1):3815. doi: 10.1038/s41467-018-05729-w.
3
Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
解析乳腺癌中的甲基化图谱：通过自动化机器学习实现的诊断和预后生物标志物
Cancers (Basel). 2021 Apr 2;13(7):1677. doi: 10.3390/cancers13071677.
4
A Novel Promoter CpG-Based Signature for Long-Term Survival Prediction of Breast Cancer Patients.一种基于启动子CpG的新型标志物用于预测乳腺癌患者的长期生存
Front Oncol. 2020 Oct 20;10:579692. doi: 10.3389/fonc.2020.579692. eCollection 2020.
5
Bacteria-related changes in host DNA methylation and the risk for CRC.宿主 DNA 甲基化与 CRC 风险相关的细菌变化。
Gut Microbes. 2020 Nov 9;12(1):1800898. doi: 10.1080/19490976.2020.1800898.
已知易患性基因座中的罕见变异及其对肺癌风险的贡献。
J Thorac Oncol. 2018 Oct;13(10):1483-1495. doi: 10.1016/j.jtho.2018.06.016. Epub 2018 Jul 4.
4
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.DNA 甲基化标志物预测转移性乳腺癌贝伐珠单抗的疗效。
Theranostics. 2018 Mar 11;8(8):2278-2288. doi: 10.7150/thno.23544. eCollection 2018.
5
Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.雌激素受体-α启动子甲基化是三阴性乳腺癌顺铂耐药预后预测的生物标志物。
Oncol Lett. 2018 Mar;15(3):2855-2862. doi: 10.3892/ol.2017.7637. Epub 2017 Dec 19.
6
Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma.DNA 甲基化的特异性或非特异性募集，一个表观遗传学困境。
Clin Epigenetics. 2018 Feb 9;10:17. doi: 10.1186/s13148-018-0450-y. eCollection 2018.
7
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.PITX2 基因启动子甲基化预测三阴性乳腺癌患者对蒽环类为基础的辅助化疗的反应。
Int J Oncol. 2018 Mar;52(3):755-767. doi: 10.3892/ijo.2018.4241. Epub 2018 Jan 8.
8
The Predictive Value of DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.DNA 甲基化对高危乳腺癌治疗的预测价值：当前指南、医学需求和挑战。
Dis Markers. 2017;2017:4934608. doi: 10.1155/2017/4934608. Epub 2017 Sep 12.
9
Cancer-related risk factors and incidence of major cancers by race, gender and region; analysis of the NIH-AARP diet and health study.癌症相关风险因素及主要癌症的发病率按种族、性别和地区划分；美国国立卫生研究院-美国退休人员协会饮食与健康研究分析。
BMC Cancer. 2017 Aug 30;17(1):597. doi: 10.1186/s12885-017-3557-1.
10
Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?癌症易感性和生存率的种族差异：仅仅是肤色的问题吗？
Trends Cancer. 2017 Mar;3(3):181-197. doi: 10.1016/j.trecan.2017.02.002. Epub 2017 Mar 6.